Matthew L. Sherman
2020 - Deciphera Pharmaceuticals
In 2020, Matthew L. Sherman earned a total compensation of $1.3M as EVP, Chief Medical Officer at Deciphera Pharmaceuticals, a 75% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $307,461 |
|---|---|
| Option Awards | $385,576 |
| Salary | $504,986 |
| Stock Awards | $96,571 |
| Other | $5,962 |
| Total | $1,300,556 |
Sherman received $505K in salary, accounting for 39% of the total pay in 2020.
Sherman also received $307.5K in non-equity incentive plan, $385.6K in option awards, $96.6K in stock awards and $6K in other compensation.
Rankings
In 2020, Matthew L. Sherman's compensation ranked 7,477th out of 13,090 executives tracked by ExecPay. In other words, Sherman earned more than 42.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,477 out of 13,090 | 43rd |
Division Manufacturing | 3,144 out of 5,621 | 44th |
Major group Chemicals And Allied Products | 1,269 out of 2,254 | 44th |
Industry group Drugs | 1,097 out of 1,954 | 44th |
Industry Pharmaceutical Preparations | 818 out of 1,459 | 44th |
Source: SEC filing on April 26, 2022.
Sherman's colleagues
We found four more compensation records of executives who worked with Matthew L. Sherman at Deciphera Pharmaceuticals in 2020.